嘧啶酮mhcpe,2-甲基-3 H -5-羟基-6-羧基-4-嘧啶酮乙酯(mhcpe,1),2,3-二甲基-5-苄氧基-6-羧基-4-嘧啶酮乙酯(合成dbcpe,2)和N-甲基-2,3-二甲基-5-羟基-6-羧基酰胺基-4-嘧啶酮(N -MeHOPY,3),并通过单晶X射线衍射确定其结构。通过电位分光光度法和分光光度法研究了1的酸碱性质,p K a值为1.14和6.35。进行DFT计算以确定H 2 L +,HL和L各自的最稳定结构−形成(HL = mhcpe)并分配参与质子化-去质子化过程的基团。所述mhcpe -配体形成稳定复合物为V IV ø 2+在pH值范围为2至10,并且电位,EPR和紫外可见技术来鉴定和表征在V IV形成O形mhcpe物种。结果与V IV O,(V IV O)L,(V IV O)L 2,(V IV O) 2 L 2 H -2,(V IV O)L 2 H -1, (V
A novel VIVO–pyrimidinone complex: synthesis, solution speciation and human serum protein binding
作者:Gisela Gonçalves、Isabel Tomaz、Isabel Correia、Luís F. Veiros、M. Margarida C. A. Castro、Fernando Avecilla、Lorena Palacio、Miguel Maestro、Tamás Kiss、Tamás Jakusch、M. Helena V. Garcia、João Costa Pessoa
DOI:10.1039/c3dt50553g
日期:——
Calculations indicate that the global binding ability of mhcpe towards VIVO2+ is similar to that of maltol (Hmaltol = 3-hydroxy-2-methyl-4H-pyran-4-one) and lower than that of 1,2-dimethyl-3-hydroxy-4-pyridinone (Hdhp). The interaction of VIVO-complexes with human plasma proteins (transferrin and albumin) is studied by circular dichroism (CD), EPR and 51V NMRspectroscopy. VIVO–mhcpe–protein ternary complexes
嘧啶酮mhcpe,2-甲基-3 H -5-羟基-6-羧基-4-嘧啶酮乙酯(mhcpe,1),2,3-二甲基-5-苄氧基-6-羧基-4-嘧啶酮乙酯(合成dbcpe,2)和N-甲基-2,3-二甲基-5-羟基-6-羧基酰胺基-4-嘧啶酮(N -MeHOPY,3),并通过单晶X射线衍射确定其结构。通过电位分光光度法和分光光度法研究了1的酸碱性质,p K a值为1.14和6.35。进行DFT计算以确定H 2 L +,HL和L各自的最稳定结构−形成(HL = mhcpe)并分配参与质子化-去质子化过程的基团。所述mhcpe -配体形成稳定复合物为V IV ø 2+在pH值范围为2至10,并且电位,EPR和紫外可见技术来鉴定和表征在V IV形成O形mhcpe物种。结果与V IV O,(V IV O)L,(V IV O)L 2,(V IV O) 2 L 2 H -2,(V IV O)L 2 H -1, (V